Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 2/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987158 | 0.91 | NT5E (0.53) | NT5E | |
| SCHEMBL19987308 | 0.89 | CYP3A4 (0.45) | DNPH1CYP3A4CYP2C9 | |
| SCHEMBL21511201 | 0.89 | CYP3A4 (0.45) | DNPH1CYP3A4CYP2C9 | |
| SCHEMBL19987378 | 0.87 | DNPH1 (0.44) | DNPH1NT5EP2RX3P2RX2ADORA3 | |
| SCHEMBL19987319 | 0.87 | CYP3A4 (0.42) | DNPH1NT5EP2RX3P2RX2ADORA3 | |
| SCHEMBL19987311 | 0.87 | CYP3A4 (0.46) | DNPH1NT5EP2RX3P2RX2ADORA3 | |
| SCHEMBL19987170 | 0.86 | NT5E (0.53) | NT5EADORA3 | |
| SCHEMBL19987207 | 0.86 | NT5E (0.52) | NT5E | |
| SCHEMBL19987168 | 0.85 | NT5E (0.52) | NT5E | |
| SCHEMBL19987334 | 0.84 | CYP3A4 (0.42) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2019-10-24 | — | — | US | disclosed |
| WO-2018049535-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | PNP, TYMP, MTAP | DNPH1 1314/4885NT5E 63/4885P2RX3 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.